ライフサイエンスコーパス: animal model

1 eneration of dehiscence-type defects in this animal model.

2 with rituximab in a rituximab-sensitive NHL animal model.

3 n greatly hindered because of the lack of an animal model.

4 incidence of diabetes, both in humans and in animal models.

5 onic cuprizone and acute lysolecithin rodent animal models.

6 ctive in both prophylactic and postinfection animal models.

7 efficiently deliver hydrophobic molecules to animal models.

8 be captured by using surrogate cell lines or animal models.

9 ts potent neuroprotective effects in various animal models.

10 oorly understood due to a historical lack of animal models.

11 ve been shown to have hepatotoxic effects in animal models.

12 exerts profound anti-inflammatory effects in animal models.

13 t PLG was able to identify metastatic LNs in animal models.

14 od, largely due to the reliance on non-human animal models.

15 d with alcohol dependence in both humans and animal models.

16 f protection against flavivirus infection in animal models.

17 ectroencephalographic sleep in humans and in animal models.

18 en widely reported in depressed patients and animal models.

19 ogical systems ranging from cell cultures to animal models.

20 o study fine details of protein synthesis in animal models.

21 s, SARS-CoV-1, and SARS-CoV-2 replication in animal models.

22 dihydrocollidine (DDC)-fed mice were used as animal models.

23 oV-2 has been affected by a lack of suitable animal models.

24 udies of TF-mediated gene regulation in live animal models.

25 nxiolytic and antidepressive-like effects in animal models.

26 goals is the paucity of suitable preclinical animal models.

27 rus pathogenesis and therapeutic research in animal models.

28 ced dissemination and increased mortality in animal models.

29 , and prevented liver injury in experimental animal models.

30 ing following myocardial infarction in small-animal models.

31 lts demonstrated in a range of live cell and animal models.

32 systems, including patient-derived cells and animal models.

33 prevent transmission and block infection in animal models.

34 icacy of BMP signaling inhibitors in two pSS animal models.

35 rization associated with retinal diseases in animal models.

36 treatment of heart failure in 2 preclinical animal models.

37 pertussis and prevents nasal colonization in animal models.

38 errepresented in research due to the lack of animal models.

39 response patterns demonstrated in non-human animal models.

40 infections by influenza, Ebola, or HIV-1 in animal models.

41 aking them difficult to study in traditional animal models.

42 lating complex human disease to reductionist animal models.

43 to replace or reduce the dependence on using animal models.

44 e metabolic diseases in humans as they do in animal models.

45 n to have anxiolytic effects in a variety of animal models.

46 In animal models, a major factor driving progression from p

47 However, questions remain whether small animal models accurately predict efficacy in humans.

48 affected, whereas pathology of patients and animal models also indicates involvement of skeletal mus

49 d characterized a variety of RGC subtypes in animal models, although only a handful of studies demons

50 e range of pulmonary disorders in humans and animal model analogs.

51 In the DEN-induced animal model and clinical hepato-carcinoma samples, high

52 n in a post-traumatic stress disorder (PTSD) animal model and was related to reducing PTSD symptom de

53 s translational challenges between available animal models and clinical heart transplant settings tha

54 can accurately translate between preclinical animal models and clinical human studies.

55 eneficial effects on intestinal integrity in animal models and clinical trials.

56 tective immunity have been performed only in animal models and correlates of protection have not been

57 this knowledge can inform studies in higher animal models and help to develop treatments to combat h

58 has been associated with CKD progression in animal models and human biopsy specimens.

59 d astrocyte-endothelial interactions in both animal models and human brain metastasis samples.

60 ystematic review of the literature from both animal models and human studies that highlight the impor

61 rum disorder (ASD) has been explored through animal models and human studies with microbiome assessme

62 However, previous data from both animal models and human subjects showed that inflammator

63 Both research from animal models and human-level theories of action control

64 k to bring together findings from studies in animal models and humans and to bridge the gap between r

65 on, food intake and/or energy expenditure in animal models and humans.

66 g as the initial trigger of pathology in our animal models and humans.

67 establish treatment efficacy in pre-clinical animal models and in patients infected with T. cruzi.

68 sorbed (AVA), which is protective in several animal models and induces neutralizing antibodies agains

69 rodegenerative diseases in both cellular and animal models and may lead to clinically useful reagents

70 the link has been supported by experimental animal models and observational studies in humans, findi

71 of YME1L and noncanonical Notch signaling in animal models and patient cells support their fundamenta

72 downmodulates skin inflammatory responses in animal models and psoriasis clinical samples.

73 ing to how well they can be recapitulated by animal models and quantify similarities between human di

74 ng both microbe and host) both impact CVD in animal models and show striking clinical associations in

75 This review highlights the value of animal models and the power of combining pre-clinical an

76 Using animal models and theoretical multicellular linear stran

77 include data from in vitro systems, genetic animal models, and AD-derived human tissue, and discuss

78 body of empirical data, derived largely from animal models, and associated theoretical modelling, it

79 he natural hosts, interspecies transmission, animal models, and molecular basis of receptor binding f

80 r the virological and immunological lessons, animal models, and tools developed in response to prior

81 Data from both humans and animal models are consistent in demonstrating that vapin

82 Animal models are crucial for studying the effects of mu

83 of astrocytes in PML pathogenesis.IMPORTANCE Animal models are crucial in advancing biomedical resear

84 Further testing in live animal models are indicated.

85 search, however, studies using translational animal models are limited.

86 Studies in animal models are needed to demonstrate whether neurolog

87 tion and in vivo evaluation in translational animal models are of general applicability and answer ne

88 Nonetheless, animal models are of great utility to investigate inflam

89 Animal models are urgently being developed for SARS-CoV-

90 Animal models are useful for exploring the health conseq

91 s mast cells and that has shown potential in animal models as a treatment for eosinophilic gastritis

92 In support of this hypothesis, studies in animal models as well as human subjects have shown that

93 those aspects, primarily because of the few animal models available as natural hosts that are compat

94 n signalling suppresses insulin secretion in animal models (but not in humans), is potently obesogeni

95 w-flow extracorporeal CO2 removal in a large animal model, but the final dialysis dose delivered need

96 es irradiation-impaired salivary function in animal models, but the underlying mechanisms are largely

97 pure betalains were tested in vivo using the animal model C. elegans.

98 potential treatments, preclinical data from animal models can guide the search for effective treatme

99 tributes coupled with minimal ototoxocity in animal models combine to make apramycin an excellent sta

100 t-7 miRNAs and other RNA targets-in cell and animal models confers a less aggressive/metastatic pheno

101 f transcriptomic data from autopsy cases and animal models confirms that immunosuppression is also pr

102 Studies with animal models could test such approaches and assess ther

103 Reviewing SARS-CoV-2 animal model data facilitates standardization and harmon

104 Experimental animal models demonstrate that maternal immune activatio

105 Animal models demonstrating end-organ protection in C3-d

106 We summarize also the main cellular and animal models developed to date and the possible future

107 s are consistently observed in AD transgenic animal models devoid of such pathologies, bringing into

108 tifying novel familial mutations, generating animal models, elucidating molecular mechanisms, and ult

109 been the main focus of MS research using the animal model experimental autoimmune encephalomyelitis (

110 hogenesis of multiple sclerosis (MS) and its animal model, experimental autoimmune encephalomyelitis

111 the CNS, such as multiple sclerosis and its animal model, experimental autoimmune encephalomyelitis

112 In animal models, exposure to unpredictable patterns of mat

113 ecies, our data also suggest that transgenic animal models expressing human ACE2, such as the hACE2 t

114 counterparts) and neurophysiology studies in animal models, facilitated in large part by optogenetic

115 l ADPKD therapies with promising outcomes in animal models failed to be translated to human disease,

116 Using a promising animal model for action tremor, our results thus charact

117 The rhesus macaque is an important animal model for AIDS and other infectious diseases.

118 guide for selecting the most appropriate CF animal model for any given application.

119 data support the D2.mdx as a superior small animal model for DMD, as compared to the B10.mdx model.

120 pathogen extensively employed as a surrogate animal model for EHEC.

121 The gold standard small animal model for JUNV infection is the guinea pig.

122 ental autoimmune encephalomyelitis (EAE), an animal model for MS.

123 ood and several brain regions of a validated animal model for SCZ at baseline.

124 notypes were reported to be reversed in this animal model for SCZ, showed a significant NDEL1 activit

125 for HCC are limited for lack of a convenient animal model for study in HCV infection and liver pathog

126 aluate multiple behavioral alterations in an animal model for the study of depression, which provides

127 young pig may, therefore, be a useful large animal model for the study of eosinophilic esophagitis i

128 al species as possible intermediate hosts or animal models for 2019-nCoV infections.

129 Here, we develop novel severe-disease animal models for COVID-19 involving disruption of adapt

130 assembled an international panel to develop animal models for COVID-19 to accelerate the testing of

131 ppocampus, establishing canines as excellent animal models for the study of adult neurogenesis.

132 Two animal models for the study of schizophrenia endophenoty

133 Previous studies in cells and animal models had suggested that several voltage-gated C

134 n in the intra-abdominal position in a large animal model has been essential in the progression of th

135 ardiac fibrosis, and its inhibition in small-animal models has been shown to be an effective antifibr

136 Intensive research using these animal models has revealed shared molecular mechanisms t

137 Multiple animal models have been developed in an attempt to recre

138 l" AF is nearly nonexistent in most species, animal models have contributed significantly to our unde

139 Recent discoveries using tumor bearing animal models have eluded to the autonomic nervous syste

140 Studies in animal models have identified molecular cues propagated

141 Animal models have proved invaluable in revealing a weal

142 otherapy agents, which have shown promise in animal models, have failed in clinical trials due to dos

143 Using cell culture and animal models, here we sought to identify the effects of

144 In mammalian animal models, high-resolution kinematic tracking is res

145 ent organoids, corroborating the findings in animal models; however, patient-derived organoids mainta

146 In animal models, immunity to mosquito salivary proteins pr

147 ture of this dysconnectivity is unknown, but animal models imply dysfunctional theta phase coupling b

148 nd promote oxidative metabolism in cells and animal models in a SIRT1-dependent manner.

149 With the increasing necessity of animal models in biomedical research, there is a vital n

150 ) devices are miniaturized devices replacing animal models in drug discovery and toxicology studies.

151 been impeded by the limitations of available animal models in reproducing many of the clinical featur

152 ing is further underscored by the absence of animal models in the case of human-restricted viruses, s

153 SARS-CoV-2 can be studied in detail only in animal models, in which repeated sampling and tissue col

154 singly being incorporated into complementary animal models, including escalation of drug intake, puni

155 ideally would be obtained from (1) improved animal models, including large animal models, which inco

156 RNA-based studies conducted mainly in large-animal models, including pigs, rabbits, dogs, and nonhum

157 In an anaesthetised animal model, independent stimulation of baroreceptors i

158 f samples from patients, and observations in animal models, indicate that platelets may drive lung in

159 herefore, the coordination and assessment of animal models is imperative.

160 diseases like diabetic retinopathy in small animal models is often complicated by their failure to d

161 ons can vary considerably between assays and animal models, leading to very different predictions of

162 ity-associated microbiotas to weight gain in animal models, microbiota resilience may need to be over

163 small laboratory animals, but its effect on animal models more closely related to humans, such as no

164 led ventilation attenuates lung injury in an animal model of acute respiratory distress syndrome.

165 that primed PMNs were tested in a two-event animal model of ARDS to identify a molecular link betwee

166 owed significant antifibrotic efficacy in an animal model of bleomycin-induced pulmonary fibrosis.

167 chc function and to develop the first viable animal model of cblC deficiency.

168 ile rehabilitation to improve recovery in an animal model of chronic sensory loss.

169 Using an animal model of CIPS, we found that systemic administrat

170 rets represent an infection and transmission animal model of COVID-19 that may facilitate development

171 GF-dependent retrograde signaling, and in an animal model of FD it rescued abnormal sympathetic targe

172 This data further validates our animal model of GDM and is usefulness in investigating t

173 tic efficacy of miR-21 inhibition in a large animal model of heart failure.

174 Here, we show in an animal model of HIV that chronic SIV-infected gut contai

175 re experimental autoimmune uveitis (EAU), an animal model of human uveitis.

176 togenetically induced sleep slow waves in an animal model of ischemic stroke and identify sleep as a

177 roven feasibility and biocompatibility in an animal model of ligament reconstruction.

178 Using an animal model of MS, experimental autoimmune encephalomye

179 ental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis (MS).

180 ental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis.

181 We developed a large animal model of MVID that has many features of the human

182 rsal study was performed in the diet-induced animal model of NAFLD (DIAMOND).

183 These findings validate a novel animal model of nicotine vapor self-administration in ro

184 hogenesis of AD using GiD, a newly developed animal model of reactive astrocytes, where the reactivit

185 einstatement of cocaine-seeking behavior, an animal model of relapse.

186 unit recording techniques and an established animal model of seizure (picrotoxin) to determine the ef

187 n against human tuberculosis and a validated animal model of the disease, tools to facilitate vaccine

188 7A deficiency and tested their effects in an animal model of the disease.

189 ion thereby preventing epileptogenesis in an animal model of TLE.

190 In a large animal model of vascular embolization, it is shown that

191 ed to assess level of arousal and applied to animal models of a range of neurological disorders.

192 te cyst formation and disease progression in animal models of ADPKD.

193 or (ETX001) were evaluated in human cell and animal models of airway epithelial function and mucus tr

194 The development of animal models of antiglycolipid antibody-mediated neurop

195 tial in whole blood, isolated platelets, and animal models of arterial injury.

196 related responses have also been observed in animal models of BDNF deficiency in vivo, and BDNF is a

197 In animal models of cancer, oncologic imaging has evolved f

198 ut hamster model to expand the repertoire of animal models of CCHFV pathogenesis that can be used for

199 ous solubility (27 muM), limiting its use in animal models of chronic disease.

200 in-wide rearrangements of the vasculature in animal models of congenital deafness and ischemic stroke

201 ethods for modeling CRC have been developed, animal models of CRC remain helpful when analyzing molec

202 Animal models of cystic fibrosis (CF) are essential for

203 Useful animal models of disease in neuroscience can make accura

204 to confounding translation from preclinical animal models of disease to clinical cohorts.

205 d studies identified marked heterogeneity in animal models of donor brain death coupled to HTx, with

206 umans presents a rich opportunity to sharpen animal models of eating disorders and to identify neural

207 ificantly reduced allergic response in three animal models of FA, with a stimulation of tolerogenic c

208 In animal models of HD, nucleocytoplasmic transport is disr

209 In animal models of HF, central inhibition of RAS and pro-i

210 Current ex vivo and animal models of hidradenitis suppurativa (HS) display i

211 derived from studies of patients with MS and animal models of how specific cytokines produced by auto

212 Animal models of human antigen-specific B cell receptors

213 elopment pipeline necessitates studies using animal models of human disease to gauge future efficacy

214 Small animal models of JUNV infection are limited because most

215 cells and test their therapeutic efficacy in animal models of neurological diseases.

216 ere we demonstrated target engagement in two animal models of neuropathic lysosomal storage diseases

217 ssion, suggesting limitations in preclinical animal models of neurotoxicity.

218 se and consequences of vaping is the lack of animal models of nicotine vapor self-administration.

219 generation and neuroinflammation in multiple animal models of PD.

220 data, due primarily to a paucity of relevant animal models of penile HIV infection.

221 We also review findings from multiple animal models of preeclampsia.

222 in animals, this has not yet been applied to animal models of psychiatric disease.

223 proves functional and structural outcomes in animal models of retinal injury and retinal degenerative

224 d decrease mortality in clinical cohorts and animal models of sepsis.

225 the CNS to restore myelin has been tested in animal models of severe forms of the disease with failur

226 n vitro and inhibited disease progression in animal models of SpA.

227 Current LRRK2 PD animal models only partly reproduce the characteristics

228 r vasculature in human-relevant TMJ OA large animal models or in human TMJ tissues and cells.

229 ies of TPCs have used TPC(-/-) cell or whole-animal models, or Ned-19, an indirect inhibitor.

230 erimental data from physiologically relevant animal models, our knowledge of the trafficking signals

231 owed by validating them in the most suitable animal models prior to initiating human clinical trials.

232 placenta in different species, meaning that animal models provide limited information about human pl

233 While animal models provide the experimental flexibility to an

234 Animal models provide valuable mechanistic insights, but

235 In the animal model, PT2385 single-agent treatment did improve

236 Animal models recapitulating human COVID-19 disease, esp

237 have been hampered by the lack of available animal models recapitulating the human disease.

238 echanistic disease progression studies using animal models require objective and quantifiable assessm

239 Experimental animal models show changes in the gut microbiome and imm

240 t magnetic susceptibility imaging in a large animal model shows an infarct paramagnetic shift associa

241 rom Curcuma longa (Curcuminoids) in a Stelic animal model (STAM) of NASH.

242 Timing of the intervention, choice of animal models, strategy for drug selection, and lack of

243 Despite numerous animal model studies, questions remain about local immun

244 has been shown through numerous mechanistic animal model studies.

245 However, only large animal models such as macaques are thought to reproduce

246 lutions(6), particularly in diseases lacking animal models, such as DiHS/DRESS.

247 hypothesis that could be tested in relevant animal models, such as nonhuman primates.

248 Research in humans and animal models suggests that visual responses in early vi

249 However, in the natural animal model system of Marek's disease alphaherpesvirus

250 , and tumor-immune-system interactions in an animal model system.

251 e development and testing of therapeutics in animal model systems and in humans is provided.

252 complex and potentially inconsistent across animal-model systems and in humans.

253 y virus (HIV) cure is the lack of a scalable animal model that enables robust evaluation of eradicati

254 utcomes-related data in experiments with the animal models that are essential for understanding kidne

255 We further present advances in animal models that are important for understanding the p

256 rfacing with fine peripheral nerves in small animal models that begins to meet these constraints.

257 likely require demonstration of efficacy in animal models that faithfully reproduce the human condit

258 asible diagnostic tools for HFpEF, including animal models that recapitulate human HFpEF, and human s

259 Currently, the cachexia field lacks animal models that recapitulate the long-term kinetics o

260 cuing salivary gland function in a number of animal models that reflect human diseases and that resul

261 demonstrated in 1 or more well-characterized animal models that sufficiently represent human disease.

262 We present 2 new animal models that will serve to elucidate the underlyin

263 oncogenic functions of E2A-PBX1 in cell and animal models, the E2A-PBX1-enforced cistrome, the E2A-P

264 omplete protection against bubonic plague in animal models, the mechanisms responsible for this antib

265 In animal models, the peptide displayed direct antimicrobia

266 rscores the imperative for establishing good animal models, then gleaning all available data on effic

267 ve developed into promising alternatives for animal models; these systems integrate engineered human

268 to diverse disease states using clinical or animal-model tissue samples.

269 In orthotopic xenograft animal model, TMPRSS2 overexpression promoted prostate c

270 se mechanistic observations in a preclinical animal model to design an ex vivo platform that recreate

271 We established a novel animal model to examine the effects of long-term use of

272 hieving this goal is the lack of a tractable animal model to study PML pathogenesis.

273 e results establish C. elegans as a powerful animal model to study the induction and modulation of fe

274 The most commonly used animal model to study the pathogenesis of human sepsis i

275 irway epithelial cells could serve as higher animal models to examine the relationships between funga

276 lopment of antitoxin approaches and improved animal models to explore these approaches.

277 provides a roadmap for applying findings in animal models to individualized therapy that targets aff

278 These studies will help develop animal models to more accurately resemble human immune r

279 In animal models, treatment with epigenetic modifiers can m

280 Animal models used in the study of ASD frequently recapi

281 S disc morphogenesis, we generated a Prcd-KO animal model using CRISPR/Cas9.

282 w that the approach can be extended to other animal models, using chicken embryos.

283 ofile after serial transmissions in a single animal model, was based on the direct interaction of pri

284 entation have been well studied in human and animal models, we are still learning much about the cell

285 Here, using cultured cells and two animal models, we demonstrate that lipoprotein-derived f

286 mbination of in vitro approaches and in vivo animal models, we show that endotoxin treatment induced

287 ission tomography-magnetic resonance imaging animal models, we showed that protein arginine N-methylt

288 Animal models, when appropriate, can guide/inform medica

289 the arterial system of a pre-clinical ovine animal model, where they endothelialized within one mont

290 Herein, we used an animal model, wherein NC1-peptide cloned into the pCI-ne

291 Previous observations have relied on animal models, which differ from humans in both their de

292 (1) improved animal models, including large animal models, which incorporate the effects of aging an

293 ous brain and genetic studies, in humans and animal models, which serve as reassuring de facto positi

294 In animal models, whole-body receptor Notch3 deficiency pro

295 sittacus undulatus; of either sex), an avian animal model with complex hearing abilities similar to h

296 ecently, microglia have been studied only in animal models with exogenous or transgenic labeling.

297 Animal models with localized tau expression are used to

298 indered by the almost exclusive use of a few animal models with restrictive monogenic backgrounds tha

299 nes, patient-derived cells, and pre-clinical animal models, with one compound currently undergoing a

300 e human genetics studies and recent in utero animal modeling work suggest that precise control of ion